ERBB2 and breast cancer: This same phenomenon was recently observed in women enrolled in the adjuvant Tykerb Evaluation after Chemotherapy (TEACH) clinical trial [25], where patients with HER2 positive operable breast cancer not receiving adjuvant trastuzumab were randomized to adjuvant lapatinib or observation at a median time from diagnosis of 70 months.